Hikari Power’s Carisma Therapeutics CARM Stock Holding History

Hikari Power’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,593	Closed	-$220K	–	89
2019 Q4	$220K	Hold	10,593	–	–	0.02%	93
2019 Q3	$248K	Hold	10,593	–	–	0.03%	86
2019 Q2	$318K	Sell	10,593 -10	-0.1%	-$299	0.03%	83
2019 Q1	$218K	Buy	10,603 +378	+4%	+$6.53K	0.02%	112
2018 Q4	$290K	Buy	10,225 +6,945	+212%	+$222K	0.03%	86
2018 Q3	$141K	Buy	+3,280	New	+$128K	0.01%	126

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hikari Power's CARM Position: Q1 2020 in Review

Hikari Power sold out of Carisma Therapeutics (CARM) in Q1 2020, closing a stake of 10,593 shares — an estimated $220K sold.

Hikari Power first reported a position in CARM in Q3 2018 and held it in 6 quarters. The position peaked at $318K in Q2 2019. 36 funds tracked by Wall St. Rank hold CARM as of Q1 2020.

Hikari Power reported no remaining Carisma Therapeutics position as of Q1 2020 after selling out during the quarter.
Hikari Power sold 10,593 Carisma Therapeutics shares in Q1 2020, an estimated $220K.
Hikari Power first reported a position in Carisma Therapeutics in Q3 2018 and held it in 6 quarters.
Hikari Power's Carisma Therapeutics position peaked at $318K in Q2 2019.
36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2020.

Based on Hikari Power's 13F filing for Q1 2020, filed 23 Apr 2020.